Slow Capital Inc. Purchases 5,346 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Slow Capital Inc. raised its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 7.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 82,001 shares of the medical research company’s stock after buying an additional 5,346 shares during the period. Slow Capital Inc.’s holdings in Exact Sciences were worth $4,608,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of EXAS. Chicago Partners Investment Group LLC boosted its stake in shares of Exact Sciences by 1.7% in the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock worth $651,000 after acquiring an additional 158 shares during the period. Amalgamated Bank increased its position in shares of Exact Sciences by 2.7% during the second quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock worth $462,000 after acquiring an additional 284 shares during the period. Huntington National Bank lifted its holdings in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after buying an additional 352 shares during the period. CIBC Asset Management Inc lifted its position in shares of Exact Sciences by 6.1% in the 3rd quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after purchasing an additional 371 shares during the period. Finally, Advisors Asset Management Inc. boosted its position in Exact Sciences by 1.4% during the 3rd quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock valued at $1,952,000 after acquiring an additional 402 shares in the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on EXAS. Citigroup dropped their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Barclays assumed coverage on Exact Sciences in a report on Thursday, January 23rd. They issued an “overweight” rating and a $70.00 price target for the company. Jefferies Financial Group lifted their target price on shares of Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Bank of America dropped their price target on Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, Robert W. Baird lowered their price target on shares of Exact Sciences from $70.00 to $67.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Exact Sciences presently has an average rating of “Moderate Buy” and an average price target of $72.76.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy acquired 19,500 shares of Exact Sciences stock in a transaction that occurred on Wednesday, November 13th. The stock was purchased at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the purchase, the chief executive officer now owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. The trade was a 1.85 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.36% of the stock is owned by corporate insiders.

Exact Sciences Trading Down 0.5 %

Shares of NASDAQ:EXAS opened at $55.68 on Tuesday. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The firm has a market cap of $10.31 billion, a P/E ratio of -47.59 and a beta of 1.24. The company has a 50 day moving average of $57.66 and a 200-day moving average of $59.68.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The firm had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. As a group, analysts anticipate that Exact Sciences Co. will post -1.1 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.